HLAG antibody (FITC)
-
- Target See all HLAG Antibodies
- HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))
-
Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This HLAG antibody is conjugated to FITC
-
Application
- Flow Cytometry (FACS)
- Specificity
- The antibody MEM-G/11 recognizes an extracellular epitope of HLA-G1 antigen. HLA-G belongs to the MHC Class I molecules (MHC Class Ib, nonclassical) and it is expressed on the surface of trophoblast cells.
- Cross-Reactivity (Details)
- Human
- Purification
- Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- Immunogen
- Recombinant human HLA-G refolded with beta2-microglobulin and peptide.
- Clone
- MEM-G-11
- Isotype
- IgG1
- Top Product
- Discover our top product HLAG Primary Antibody
-
-
- Application Notes
- Flow cytometry: The antibody MEM-G/11 does not cross-block standard MEM-G/9 antibody. Recommended dilution: 1-3 μg/mL.
- Comment
-
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC.
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handling Advice
-
Do not freeze.
Avoid prolonged exposure to light. - Storage
- 4 °C
- Storage Comment
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
Disulfide bond-mediated dimerization of HLA-G on the cell surface." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 25, pp. 16180-5, (2002) (PubMed).
: "
-
Disulfide bond-mediated dimerization of HLA-G on the cell surface." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 25, pp. 16180-5, (2002) (PubMed).
-
- Target
- HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))
- Alternative Name
- HLA-G (HLAG Products)
- Synonyms
- MHC-G antibody, B-F antibody, B-F-S04 antibody, B-F-S05 antibody, B-F-S06 antibody, B-F-S07 antibody, B-FI antibody, B-FIV antibody, BF2 antibody, BFa2 antibody, BFw-03 antibody, BFw-05 antibody, BFz-01 antibody, major histocompatibility complex, class I, G antibody, MHC BF1 class I antibody, HLA-G antibody, BF1 antibody
- Background
- Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.
- Gene ID
- 3135
- UniProt
- P17693
- Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-